Is a Cheaper Wegovy Creating More Competition?
Competition from less expensive weight-loss drugs has prompted Danish drugmaker Novo Nordisk A/S to announce cuts to pricing for GLP-1 products Wegovy and Ozempic.
Novo’s GLP-1s will cost $675 a month across the board, down from $1,349.02 for Wegovy, pill or injection, and $1,027.51 for Ozempic and Rybelsus, injection and pill, respectively. The prices compare to $1,086.37 for Eli Lilly’s Zepbound. Lilly currently has 60% of the GLP-1 market, Novo’s has declined to about 40%. Prices took effect Jan. 1.
“I’m confident that payers will accept and welcome these lower list prices, as they’ve been calling for them publicly,” Jamey Millar, Novo’s U.S. operations chief, told Bloomberg.
Excerpted from The Food Institute
